ArticleFrontiers in pharmacology2025

Addition of bevacizumab to gefitinib plus chemotherapy as first-line therapy in EGFR L858R mutate advanced non-small cell lung cancer patients.

Lingli Lei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.